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Introduction
Pharmacogenetics and pharmacogenomics, 
have often been hailed as the holy grail of 
therapeutics. Scientists have seen them as 
a major highway leading to personalized 
medicine, where the patient’s most personal 
characteristic, his genetic profile, becomes 
a fingerprint which can be used to predict 
the way he will respond to a specific drug. 
Therapeutic outcome data collected from 
large clinical trials, may start to lose its 
meaning, unless those trials are also fortified 
with pharmacogenomic considerations. 
Standardized dosing, may give way to 
genotype-predicted dosing, perhaps reducing 
the need for clinically-based individual dose 
adjustments. Therapeutic drug monitoring 
data may be combined with genotype data, 
in order to enhance the maintenance of 
drug levels within the required therapeutic 
window. The benefit to risk ratio for most 
drugs may be improved, with consequently 
less adverse events, better therapeutic 
outcomes and improved pharmacoeconomic 
prospects. 
Timeline
Science rapidly makes history. Watson 
and Crick published their cardinal paper 
describing the double-helical structure of 
DNA in 1953.2 In 1957, Motulsky suggested 
that individual differences in drug efficacy 
and adverse effects might be due to 
inheritance.3 Two years later, Vogel published 
his “Moderne problem der humangenetik”4 
wherein for the first time, the term 
“pharmacogenetics” was coined and used. 
This was followed by a landmark paper in 
1968, where Vessel and Page showed similar 
drug pharmacokinetics in identical twins who 
share 100% of their genes as contrasted to 
fraternal twins who only share 50%.5   This 
period even preceded the development of 
DNA sequencing technologies, which started 
to emerge in the 1970s.  Scientific interest 
in the pharmacogenetic area gradually 
began to increase, and further landmarks 
were reported.  However, it was only in the 
mid-1990s that a sudden escalation of peer-
reviewed publications occurred, as evidenced 
by the National Centre for Biotechnology 
Information (NCBI)-maintained Pubmed 
database indices. During this period, the 
US-funded human genome project was 
underway, and interest in the functional 
relevance of DNA sequences was increasing 
in the scientific community. The completion 
and public availability of the human genome 
project data in April 2003, ushered us into 
“Our drugs do not work on most patients.” Such did Allen Roses, 
then worldwide vice-president of genetics at GlaxoSmithKline, greet 
his audience, during a scientific meeting in London in 2003.1 Nearly 
a decade has passed since then, and significant strides towards 
the development of genotype-guided prescribing have been made. 
Pharmacogenetics and pharmacogenomics are now an established area 
of pharmacology specialization, and they hold the promise of the key 
to personalized medicine, leading to safer and more effective patient-
focussed therapeutic outcomes.
•	 To	emphasize	the	importance	of	genetic	contributions	to	observed	interpatient	
variablity in drug responses
•	 To	discuss	the	practical	applications	of	pharmacogenetic/pharmacogenomic	
knowledge
•	 To	suggest	how	the	introduction	of	pharmacogenetic	tools	may	require	additional	
skills from health care professionals
•	 To	provide	a	basic	picture	of	the	roles	being	undertaken	by	FDA	and	EMA	with	respect	
to pharmacogenetics
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the post-genomic era. This has brought with 
it a torrent of new technologies, focussed 
on global analysis of whole genomes, rather 
than studies of individual genes. Genetics 
thus paved the way for genomics, and 
pharmacogenetics led to pharmacogenomics 
(Table 1). 
What are pharmacogenetics and 
pharmacogenomics?
The Merck Manual6 lists 26 different factors 
which can influence drug response in 
humans. These include well known variables 
such as age, gender, body weight, liver and 
kidney function and dietary factors, many 
of which are well known and are adjusted 
for, during clinical trials, and also factored 
into calculations concerning drug dosing. 
These variables are the reasons that are 
used to explain why different patients may 
respond differently to the same drug. They 
are the reasons why, similar to several other 
biological processes, therapeutic outcome 
data are better described by statistical 
distributions, rather than discrete values.
Genetic factors offer a significant 
contribution to inter-patient drug response 
variability. Estimates at quantifying this 
genetic contribution have ranged between 
20% and 95% for different drugs.7,8 
Pharmacogenetics is the study of this genetic 
variability. Its aim is to establish algorithms 
and models which could be used to associate 
DNA variations with specific therapeutic 
outcomes, and therefore use the former to 
predict the latter. Pharmacogenomics offers 
a more global approach, and encompasses 
the study of variations of DNA and RNA 
characteristics as related to drug response. 
Such work is carried out using an “–omics” 
approach, i.e. using technologies that study 
the genome (DNA) or transcriptome (RNA) as 
a global entity rather than focus on localised 
small candidate regions of interest. The 
European Medicines Agency, in 20079, offered 
the definitions shown in Table 2, in order 
to better clarify the meaning of both terms. 
Table 3 lists common terminology used in 
the fields of genetics.
What do pharmacogenetics and 
pharmacogenomics have to offer?
Throughout the years, the application of 
therapeutics has gradually shifted focus 
from the drug to the patient. The “one drug 
fits all” maxim is no longer valid, and each 
patient is now the fulcrum around which 
therapeutic options are specifically selected. 
Personalized medicine, has thus taken centre 
stage, and together with evidence-based 
prescribing, has contributed to significant 
ameliorations in patient management 
outcomes.
1953 James D Watson and Francis Crick published their paper on the double-helical structure of DNA.2
1957 Motulsky proposes that “inheritance might explain many individual differences in the efficacy of drugs and in the occurrence of 
adverse drug reactions.”3
1959 The word “pharmacogenetics” appears for the first time in a paper published by Friedrich Vogel.4
1968 Vessel and Page show similar drug pharmacokinetics in identical twins who share 100% of their genes as contrasted to fraternal 
twins who only share 50%.5
1977 DNA sequencing technologies start to emerge.
1990 The human genome project (HGP) is initiated, and funded by the National Institutes of Health (USA) and other international 
partners. Projected project timeline is 15 years.38 
2003 The HGP is completed, two years in advance of its original projected target date.38
2004 Roche AmpliChip Cytochrome P450 Genotyping test is given marketing clearance by FDA. This is the first pharmacogenetic test 
to be given FDA approval.26
2005 The European Medicines Agency (then known as EMEA, later known as EMA) establishes the Pharmacogenetics Working Party 
(PgWP). This later changed its name to the Pharmacogenomics Working Party, still maintaining the PgWP abbreviation.32
2005 The Food and Drug Administration (FDA) establishes the Interdisciplinary Pharmacogenomics Review Group (IPRG).33
2005 FDA gives marketing approval for The Invader UGT1A1 Molecular Assay. This is the first pharmacogenetic test to be approved by 
the FDA, following establishment of the IPRG.28
2009 Imperial College London announce their ongoing development of the SNP Dr pharmacogenotyping device.37
Today Major pharmaceutical companies have incorporated pharmacogenomics into the drug discovery process,, published 
pharmacogenetic data is escalating exponentially, and translation from bench to bedside is well underway.
Table 1: Some important landmarks in the pharmacogenetics timeline
Table 2: Definitions of the terms “Pharmacogenomics” and “Pharmacogenetics”  
as approved by the European Medicines Agency.9
Pharmacogenomics (PGx)
The study of variations of DNA and RNA characteristics as related to drug response.
Pharmacogenetics (PGt)
The study of variations in DNA sequence as related to drug response.
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The application of pharmacogenomic 
knowledge, aims to expand personalized 
medicine, by providing a means by which 
a patient’s most individualized variable, 
his DNA genome, can be used to predict 
therapeutic outcomes to specific drugs. 
Adverse effect profiles may also be similarly 
predicted. Such information has critical value 
for the selection of the best drug, as well 
as the best dose, for a particular patient.  
This can especially afford improved therapy 
outcomes in patients who are on narrow 
therapeutic window medications (e.g. anti-
epileptic drugs, immunosuppressant agents, 
theophylline), patients who are being treated 
with medicines that take a long time to start 
demonstrating clinical efficacy (e.g. SSRIs) 
and patients who are on drugs that may 
exhibit serious adverse reactions (e.g. anti-
cancer drugs, anti-retroviral therapy). 
The occurrence of serious adverse 
drug reactions (ADRs), is of major concern 
in therapeutics, and the major reason 
for drug withdrawals from the market. A 
recent Liverpool-based study, reported 
that 14.7% of hospital admission patients 
experienced ADRs that were due to drugs 
that were initiated or continued during 
the hospital stay10, while a Swedish-based 
study reported that 3.1% of deaths in the 
general population, are the cause of fatal 
adverse drug reactions.11 ADRs which are 
due to genetic variation, and which were 
previously considered to be unpredictable, 
may now be preventable through 
pharmacogenetics. Recommendations for 
applying pharmacogenetic knowledge for 
ADR prevention include (a) consideration 
of alternative drugs, whose action is known 
not to be subject to the genetic variation in 
question, (b) dose reduction if the prescribed 
drug is mandatory, (c) advice to the patient 
to be extra careful to monitor for adverse 
effects early in therapy, and (d) particular 
avoidance of administering multiple drugs 
whose actions are influenced by the same 
genetic variations (e.g. avoid administering 
multiple drugs which are metabolised 
by the same CYP450 enzyme, in patients 
who carry a low-activity variant for that 
enzyme).12 Table 4 lists a few examples of 
drugs whose adverse effects are well known 
to be pharmacogenetically dependent. A list 
of all drugs for which the FDA has requested 
labelling modifications in order to include 
pharmacogenetic information may be found 
on the FDA website.13
Ethnic genetic variability
Since pharmacogenetic prediction is based 
on the association of specific genetic profiles 
with specific drug responses, the differences 
in the types and frequencies of DNA variants 
found in different ethnic groups, often 
confounds the applicability of testing. For 
example, a pharmacogenetic test which has 
been developed from genetic polymorphism 
data in a Caucasian population, may have 
been optimized to genotype the 10 most 
common DNA variants which influence the 
rate of metabolism of Drug X. However, the 
Asian population, may only have a few of 
these variants, and indeed may have others 
which are not found in Caucasians. This 
often puts severe constraints on the extent 
to which pharmacogenetic tests may be put 
to use, and from a commercial aspect, limits 
the potential for worldwide distribution 
of the same testing kit or protocol. The 
implications of this also have to be seen in a 
society which is always becoming more and 
more multinational and multicultural.
How does pharmacogenomic knowledge 
arise?
Interindividual variations in the human 
genome are well known. For example, 
the SNP consortium, a group of ten large 
pharmaceutical companies and the U.K. 
Wellcome Trust, has identified about 1.8 
million single nucleotide polymorphisms in 
the human genome.14 The question which 
arises is, which of these have any importance 
to health? Which SNPs are relevant to 
disease, which are relevant to drug response, 
and which are completely harmless? And 
what about other types of genetic variation, 
such as DNA insertions, deletions and 
variable repeat sequences?
Initial pharmacogenetic studies have 
largely applied what is termed the “candidate 
gene approach.” In order to identify how 
genetics could contribute to the observed 
interpatient variability to the response 
of a drug, scientists would need to have 
detailed knowledge of the mechanism of 
action of the drug, and then intelligently 
Table 3: Common terminology used in genetics
Allele One of two or more gene variants
Candidate gene
A gene, selected on the basis of being considered important in a 
particular biological process, and therefore a potentially useful target 
to study with respect to that process.
DNA microarray
A technique to simultaneously measure several thousand potential 
alterations within a DNA sample.
Genetic marker
A known location on DNA that can assayed and used, together with 
several other genetic markers, to characterise an individual. A panel 
of genetic markers may be used as a “fingerprint” for a particular DNA 
sample or individual.
Genotype
The genetic makeup of an organism, usually referring to the presence 
or absence of one or more polymorphisms or mutations.
GWAS
Genome wide association study. A technique to identify which regions 
in a genome might be responsible for specifically observed features 
(such as a particular disease or drug response) within a population.
Mutation
A DNA variant sequence that occurs at a frequency of less than 1% in 
the general population
Polymorphism
A DNA variant sequence that occurs at a frequency of 1% or more in 
the general population
Phenotype
Features of an organism, which can be measured or observed, such as 
disease, body weight, response to a drug, eye colour etc.
SNP
Single nucleotide polymorphism. A DNA variation in which one DNA 
base is substituted by another.
select critical steps in the pathway to study 
genetically, based on the presumption that 
such steps are where it is most likely that 
genetic variability might have a phenotypic 
response. Any identified polymorphisms 
have then to be studied from a functional 
aspect, in order to prove that this variability 
is indeed responsible for the observed drug 
response variation. This has generated 
considerable valid data and indeed up to 
about 10 years ago, published studies in 
the pharmacogenetic scientific literature are 
largely based on such approaches. However 
the failure to identify pharmacogenetic 
variability cannot be underestimated in such 
studies. The fact is that we do not know 
all the mechanisms of action of every drug, 
and a cursory look through any scientific 
literature database will show that even 
today, scientists are still identifying novel 
pathways for therapeutic or adverse effects 
of established drugs which have now been 
marketed for several years.
With the advent of new research 
technologies, the candidate gene approach 
has now been making way for a newer 
pharmacogenomic approach, which does 
not rely on prior knowledge of mechanism 
of drug action.  This approach is based on 
what are termed genetic association studies, 
and from a pharmacological knowledge 
aspect, only require the clinical ability to 
be able to stratify patients into separate 
categories, based on how they respond to a 
particular drug. A group of patients, may for 
example, be prescribed a drug, and based 
on the therapeutic outcome, be grouped 
into poor responders, normal responders and 
high responders. A DNA sample from each 
patient is then screened for thousands of 
genetic markers spread throughout the whole 
genome, using a technological approach 
called a DNA microarray system. These 
markers are actually regions of DNA that 
have been well localized and studied, are 
known to be polymorphic (ie are likely to be 
different in different individuals), and are 
distributed throughout the whole genome. 
The most common type of markers used, are 
indeed SNPs. For the purposes of association 
studies, such markers may be compared to 
thousands of signposts, spread throughout 
the whole genome, with the technological 
ability for the message on every individual 
signpost to be accurately assayed and read 
using microarrays. The marker data from each 
patient is then analysed statistically, with 
the aim of identifying a small set of DNA 
markers that are statistically associated with 
a particular patient response group for the 
drug under study. Since these DNA markers 
can be easily genotyped, this approach 
generates a shortlist of DNA markers 
Drug Gene/s involved Potential adverse effect
Abacavir HLA-B*1502 Increased risk of general hypersensitivity
Azathioprine TMPT Slower metabolism and greater risk of myelotoxicity
Carbamazepine HLA-B*1502, CYP1A2 Increased risk of severe dermatological hypersensitivity reaction
Carvedilol CYP2D6 Increased risk of adverse effects in slow metabolizers
Clopidogrel CYP2C19 Reduced metabolism of the pro-drug clopidogrel, lower exposure to the active 
metabolite and lower therapeutic effect
Fluoxetine CYP2D6 Increased risk of toxicity in slow metabolizers, especially if prescribed with other 
CYP2D6-metabolized drugs
Irinotecan UGT1A1 Slower metabolism and increased risk of neutropenia
Isoniazid NAT2 Increased risk of agranulocytosis, hepatotoxicity and seizures
Nilotinib UGT1A1 Exacerbation of drug-induced jaundice
Rifampicin NAT Slower metabolism and greater risk of general adverse reactions
Warfarin CYP2C9, VKORC1 Reduced metabolism and higher bleeding risk
Table 4: Examples of drugs for which pharmacogenetic variability is known to influence the risk of adverse effects13,39
Table 5: Drugs for which dose adjustment could be considered based on Amplichip® 
CYP450 assay results
Drugs which are substrates for CYP2D6
β-blockers Carvedilol, metoprolol, propafenone, timolol
Anti-depressants Amitriptyline, clomipramine, desipramine, imipramine, 
paroxetine, venlafaxine
Antipsychotics Haloperidol, risperidone, thioridazine
Opioids Codeine, dextromethorphan, tramadol
Others Atomoxetine, flecainide, mexiletine, ondansetron, tamoxifen
Drugs which are substrates for CYP2C19
Proton pump inhibitors Omeprazole, lansoprazole, pantoprazole
Anti-epileptics Diazepam, phenytoin, phenobarbitone
Others Amitriptyline, clomipramine, cyclophosphamide, progesterone
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(essentially DNA polymorphisms) which can 
be assayed for any new patient, and which 
are statistically robust to be able to be used 
to predict into which therapeutic category 
(poor, normal or high responders, in this 
example) the patient will fall. This approach 
forms the basis of what are known as 
pharmacogenomic genome wide association 
studies (GWAS). Although more expensive 
than candidate gene approaches, GWAS have 
the advantage of not relying on the extent 
of available pharmacological knowledge of 
drug action, and have a higher success rate 
in establishing genetic profiles which are 
predictive of therapeutic or adverse reaction 
outcomes.
Pharmacogenetics, pharmacogenomics and 
pharmacy
Perhaps one of the greatest challenges of 
science is to bridge the gap between theory 
and practice. Rather than simply a matter 
of education, this is often more a question 
of implementation. Professionals within 
a health care system need to be informed 
about new therapeutic potentials, they need 
to be given access to information they can 
assimilate and they also need to be part of 
the implementation process of any novel 
tool. Both pharmacists and medical doctors 
need to understand, appreciate, and advise; 
and be knowledgeable enough to apply 
emerging pharmacogenetic principles, and 
interpret their outcomes.
“The main role of pharmacists within 
both primary and secondary care, is to supply 
medicines and to ensure this medication 
is appropriate for the individual and taken 
safely.”15 Within this context, pharmacists 
will need to take on new roles in the realm 
of pharmacogenetics, and should be in a 
position to pioneer the introduction of new 
tools as they are made available. This may 
not only require occasional participation 
at appropriate structured educational 
programmes, but also personal initiative to 
keep up to date with this rapidly developing 
field. As early as 2003, it was already 
recognised in the UK, that the level of 
genetics in most pharmacy undergraduate 
curricula was insufficient to empower 
newly emerging pharmacists with the skills 
required for the future.16 Similar observations 
were also made on pharmacy curricula 
in the US, at around the same time.17,18 
Pharmacogenetics is unfortunately still often 
viewed by academic curriculum planners, 
to be an intellectual area of study, with 
few current practical implications, and is 
therefore relegated to a lower priority level 
than, for example, pharmacodynamics and 
pharmacokinetics, both of which are widely 
recognised to merit a serious understanding, 
if one is to appreciate therapeutic and 
toxicological drug actions.  However, as early 
as 2002, a US questionnaire-based study 
carried out amongst various health care 
professionals, had already identified a high 
level of awareness that Pharmacogenetics 
will be useful to “identify patients who will 
respond to a medication”, it will “identify 
patients who are at high risk for adverse 
drug events and it will help to “determine a 
medication’s place in therapy.”19
Perhaps one reason for the relative low 
direct health care professional involvement 
at the current time, is the specialization 
of therapeutic areas in which clinical 
applications of pharmacogenetic testing 
are currently available. The translational 
period from bench to bedside is naturally 
long, and as expected, priority has been 
afforded to therapeutic areas for which it is 
more critical for outcomes to be optimized, 
such as oncology. This effectively places 
the focus of pharmacogenetics on hospital 
and specialized clinics, and less on the 
community. Such focus is however expected 
to change, as more evidence for the benefits 
of genotype-guided prescribing emerges, 
and more pharmacogenetic tests become 
available. 
Indeed, the 2006 report entitled 
‘Realising the Potential of Genomic 
Medicine’, published by the Royal 
Pharmaceutical Society of Great Britain20, 
already highlighted the importance of 
augmenting the pharmacists’ professional 
knowledge of pharmacogenetics and 
molecular medicine, in order to be prepared 
for new pharmacogenetic roles. Such roles 
may vary according to the pharmaceutical 
setting. Pharmacists working in drug 
development may be involved in the design 
and execution of pharmacogenetic arms 
of pre-marketing clinical trials, hospital 
clinical pharmacists may be involved in 
the prescription of pharmacogenetic tests, 
while community pharmacists might be 
more involved in providing information 
and advice on drug use, in connection with 
already available patient pharmacogenetic 
test results. In all cases, a sound knowledge 
of pharmacogenetic approaches, together 
with training in the correct interpretation 
of a pharmacogenetic test result, and its 
significance in pharmaceutical practice, is 
mandatory.21
Pharmacogenetics and pharmacogenomics 
in practice
Translational pharmacogenetics / 
pharmacogenomics is evolving. As selected 
pharmacogenomic biomarkers are promoted 
from “exploratory” to “qualified” status22, 
more approved tests will become available. 
The following are some robust examples of 
cases where pharmacogenetic testing has 
already been integrated into therapeutic 
drug use.
 
Izoniazid
Perhaps the earliest and most widely 
reported pharmacogenetic data, was that 
concerning the anti-tuberculous agent 
isoniazid (INAH). Isoniazid is a substrate 
for metabolism by acetylation through 
the actions of N-acetyltransferase type 
2 (NAT2). The existence of fast and slow 
acetylating individuals has been known for 
decades, and interindividual variations in 
the INAH elimination half life of over 100% 
have been reported. INAH dose adjustment 
based on NAT2 phenotype status, has been 
well studied in the literature, and this was 
initially based on phenotypic differentiation 
identified by biochemical tests. Slow 
acetylators require dose reduction, in 
order to avoid development of potentially 
serious adverse drug reactions such as 
agranulocytosis, hepatotoxicity and seizures, 
while fast acetylators require increased 
doses to attain therapeutic efficacy.23 
Extensive NAT2 pharmacogenetic studies 
have now identified specific gene variants 
that are responsible for fast acetylators and 
slow acetylators, thus replacing phenotype 
testing with genotype testing as a basis for 
determination of INAH acetylator status.
Trastuzumab 
Trastuzumab (Herceptin®) is a humanized 
monoclonal antibody against the HER2 
tyrosine kinase receptor, which is 
overexpressed in 25-30% of breast cancers. 
HER2 overexpression (HER2+) is associated 
with enhanced tumour aggression. Clinical 
studies have shown Trastuzumab to be 
effective in HER2+ patients, but only exert 
insignificant effects in HER2- individuals. 
Thus the establishment of HER2 status has 
become an important determinant to the 
use of Trastuzumab. Modern approaches 
to determine HER2 status, today include 
immunihistochemistry to semi-quantitatively 
estimate the amount of HER2 proteins 
expressed on the surface of tumour cells, 
FISH (Fluorescence In-Situ Hybridization) 
to determine the number of copies of HER2 
genes in tumour cells, and the SPoT-Light 
HER2 CISH (Subtraction Probe Technology 
Chromogenic In Situ Hybridization) test, 
which also detects the number of HER2 
gene copies in cancer cells, but is simpler to 
perform that FISH, and was approved by the 
FDA as a HER2 screening test in 2008.24
Substrates of CYP2D6 and CYP2C19
The two major cytochrome P450 enzymes, 
2D6 and 2C19 are estimated to contribute 
to the metabolism of approximately 25% 
of currently used prescription medicines 
in Europe. These enzymes are highly 
polymorphic, and several variants of their 
genes exist. Some gene variants result in 
enzyme proteins with similar activity to wild 
type, but most are responsible for enzymes 
with higher or lower activity than normal. 
Indeed, some variants produce an enzyme 
with no activity at all. Specific technical 
details may be found through the Human 
Cytochrome P450 Allele Nomenclature 
Committee.25 Therefore the rates of 
metabolism of drug substrates for CYP2D6 
and CYP2C19 are greatly dependent on the 
particular gene variants which an individual 
is carrying. 
Excessive or prolonged therapeutic effect 
or even drug-related toxicity may follow 
administration of a typical dose to a patient 
who carries a low-activity variant, by failing 
to metabolize the drug at the expected rate. 
Conversely, a patient with a high activity 
variant, may metabolize the drug at a faster 
rate than normally expected, and may be 
therefore potentially unable to maintain 
therapeutic window concentrations of the 
drug, at conventional dosing regimens. 
Adjustment of drug dosage could therefore 
be required, based upon knowledge of 
CYP2D6 and CYP2C19 genotypes.
In view of this, Roche® developed a 
DNA microarray assay (using Affymetrix® 
technology) that genotypes for 27 selected 
CYP2D6 and 3 selected CYP2C19 gene 
variants, and based on this data, predicts 
the metabolizer status of the individual.  
The test generates a predicted phenotype of 
ultrarapid, extensive, intermediate or poor 
metabolizer status, for CYP2D6 and extensive 
or poor metabolizer status for CYP2C19. Table 
5 lists a selection of CYP2D6 and CYP2C19 
substrates, which Roche® recommends be 
suitable predictive targets for the application 
of this test. The Amplichip test was approved 
by the FDA in 2004.26
Irinotecan
Irinotecan is a topoisomerase I inhibitor 
anti-cancer drug, normally used in 
combination with other chemotherapy 
agents. Its main indication is colon 
cancer, and patients may experience 
severe diarrhoea, neutropenia and 
immunosuppression as relatively common 
serious adverse effects. Following 
administration, the drug is initially 
hydrolysed to its active metabolite SN-
38, and subsequently inactivated in the 
liver by the enzyme uridine diphosphate 
glucoronosyltransferase 1A1 (UGT1A1). 
This latter inactivation step, is under the 
influence of a much studied promoter 
DNA variant which involves the insertion 
of an additional TA dinucleotide in a 
tandem repeat sequence. Patients carrying 
this variant, known as UGT1A1 allele 28 
(UGT1A1*28, (TA)6>(TA)7), produce less 
UGT1A1 than normal, and therefore take 
longer to metabolize irinotecan than 
expected. Such patients are at a higher risk 
of potentially fatal irinotecan toxicity.27 This 
has led to the commercialization of an FDA-
approved UGT1A1 genotyping assay28, and 
an FDA approved amendment to the official 
prescribing information which states that 
“Individuals who are homozygous for the 
UGT1A1*28 allele (UGT1A1 7/7 genotype) 
are at increased risk for neutropenia” and 
that “when administered in combination 
with other agents, or as a single-agent, a 
reduction in the starting dose …. should 
be considered for patients known to be 
homozygous for the UGT1A1*28 allele.” 29
Warfarin
Warfarin is a prime example of a commonly 
used drug, possessing significant inter-
patient response variability, a narrow 
therapeutic window, and the potential to 
adversely interact with a wide range of 
concomitantly administered medicines. 
Patients on warfarin need to be regularly 
and individually monitored using the 
international normalized ratio (INR) as 
European Medicines Agency Pharmacogenomics Working Party 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/contacts/CHMP/people_
listing_000018.jsp&murl=menus/about_us/about_us.jsp&mid=WC0b01ac0580028d91&jse
nabled=true
Food and Drug Administration Interdisciplinary Pharmacogenomics Review Group 
http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/
ucm083889.htm
PharmGKB Pharmacogenomics knowledge base 
http://www.pharmgkb.org/
National Center for Biotechnology Information: One size does not fit all:  
the promise of pharmacogenomics 
http://www.ncbi.nlm.nih.gov/About/primer/pharm.html
The International Union of Basic and Clinical Pharmacology. Pharmacogenomics  
and Pharmacogenetics: Introduction 
http://www.iuphar.org/sections/PGx/sec_PGx.html
Nuffield Council on Bioethics. Pharmacogenetics: ethical issues. 
http://www.nuffieldbioethics.org/pharmacogenetics
National Institute of Health. National Institute of General Medical Sciences.  
NIH Pharmacogenomics Research Network.  
http://www.nigms.nih.gov/Research/FeaturedPrograms/PGRN/
NHS, UK. National Genetics Education and Development Centre. Teaching 
pharmacogenetics. 
http://www.geneticseducation.nhs.uk/teaching-genetics/pharmacogenetics.aspx
PHG Foundation interactive tutorials. Pharmacogenomics. 
http://www.phgfoundation.org/tutorials/pharmacogenomics/index.html
Table 6: Useful pharmacogenetics and pharmacogenomics websites. 
All listed websites are live as on 30 May 2011
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an index of warfarin efficacy, and doses 
need to be regularly optimized in order to 
maintain effectiveness and minimize adverse 
reactions.
Published studies have suggested that 
over 40% of interindividual warfarin dose 
variability can be predicted by SNPs in the 
VKORC1 (1639G>A and 1173 C>T alleles) 
and CYP2C9 (CYP2C9*2 and CYP2C9*3 
alleles) genes. VKORCI codes for subunit 1 
of the warfarin target, Vitamin K epoxide 
reductase complex, while CYP2C9 partakes 
in the metabolism of both R- and S-warfarin 
enantiomers. Carriers of variant alleles are 
at higher risk for bleeding complications,30 
particularly at induction of warfarin therapy, 
and genotype-guided dosing algorithms have 
been shown to be safer and more effective 
at estimating the maintenance warfarin dose 
rather than INR monitoring alone.31 
Regulatory issues
The year 2005 saw the establishment 
of the European Medicines Agency 
Pharmacogenetics Working Party (PgWP; 
this later changed its name to the 
Pharmacogenomics Working Party)32 
and the Food and Drug Administration 
Interdisciplinary Pharmacogenomics Review 
Group (IPRG).33 Both groups work jointly, 
to prepare guidelines and provide advice; 
and extensive information about their 
activities can be found on their respective 
websites.34 One of the major actions of 
these groups has been the establishment 
of “Voluntary Exploratory Data Submission” 
(VXDS) procedures (previously called 
“Voluntary Genomic Data Submission” or 
VGDS). VXDSes constitute pharmacogenomic 
submissions that are not required as part of 
a regulatory submission, and therefore are 
not part of the regulatory decision making 
processes. They provide a platform through 
which industry is encouraged to voluntarily 
submit pharmacogenomic data to the EMA 
/ FDA, with the aim of benefitting from an 
enhanced mutual understanding of relevant 
scientific issues. Such understanding 
“may prevent delays in reviews of future 
submissions where genomics are an 
integral part of specific studies in a drug 
development program.”33  VXDS submissions 
address areas such as the genetic loci or 
gene expression profiles being explored, the 
test systems and techniques employed, the 
application of pharmacogenomic testing 
during drug development, procedures for 
transmitting, storing, and processing large 
complex data sets, and bioinformatics 
software development.22 The first joint FDA 
/ EMEA document, detailing the general 
principles to be applied in processing joint 
FDA / EMEA VGDSes was issued as early as 
200635, just one year after the establishment 
of the PgWP and IPRG working groups.
Clinical implementation of 
pharmacogenetics
The Pharmacogenomics Research Network 
of the National Institutes of Health, 
USA, set up a Clinical Pharmacogenetics 
Implementation Consortium (CPIC) in 2009, 
with the aim of addressing the “need for 
very specific guidance to clinicians and 
laboratories so that pharmacogenetic tests 
can be used wisely in the clinic.” In its 
two years of existence, the CPIC has set 
up frameworks aimed at “understanding 
the types and levels of evidence needed to 
justify incorporation of pharmacogenetics 
into clinical practice.” In particular, 
CPIC assign importance to the following 
considerations (a) a sound scientific 
rationale linking genomic variability with 
drug effects, (b) the therapeutic index 
of the involved medications, (c) the 
severity of the underlying disease, (d) the 
availability of alternative dosages or drugs 
for patients with high-risk genotypes, (e) 
the availability of approved laboratory tests, 
and (f) the availability of peer-reviewed 
Pharmacogenetics practice points for pharmacists
•	 DNA	variations	may	be	responsible	for	inter-patient	differences	in	drug	efficacy	and	
toxicity.
•	 One	specific	DNA	variant	may	influence	the	response	of	several	drugs.
•	 Variations	in	genes	which	code	for	drug	receptors,	drug	transporters,	metabolising	
enzymes, and proteins involved in signalling pathways may be especially relevant.
•	 Pharmacogenetics	aims	to	predict	drug	response	from	patient	genotypes,	and	therefore	
provide a tool for personalized optimization of drug and dose selection.
•	 A	specific	pharmacogenetic	test	is	usually	only	applicable	to	the	population	for	which	
it was developed, and not to other ethnically diverse groups. 
•	 The	correct	interpretation	of	some	pharmacogenetic	tests	may	require	prior	genetics-
based knowledge and training.
•	 The	EMA	and	the	FDA	are	both	actively	involved	in	ongoing	developments,	through	the	
establishment of the PgWP and IPRG groups.
clinical practice guidelines that incorporate 
pharmacogenetics in their recommendations. 
Electronic databases are set to be critically 
instrumental for such implementation, 
together with decision-support tools which 
will aim to integrate database information 
with laboratory pharmacogenetic test results. 
This can provide a platform through which 
genetic data can be translated to clinical 
practice.36
Future developments could see actual 
genetic testing moving out of the laboratory 
and into the clinic. The Imperial College, 
London, and its spinout company DNA 
Electronics, are currently developing a novel 
handheld device that provides on-the-spot 
pharmacogenetic testing. This device, called 
the “SNP Dr” uses DNA from saliva or cheek 
swab samples as a template for analysis, and 
performs rapid SNP assays based on a novel 
silicon chip technology, to provide “while 
you wait” pharmacogenetic predictions.37 
Such technology, will undoubtedly accelerate 
the integration of pharmacogenetic 
principles within rational prescribing 
practices. 
Conclusion
Pharmacogenetics is an evolving discipline. 
The ongoing co-operation of basic and 
clinical research with evidence-based 
science and regulatory frameworks will help 
to achieve controlled implementation of a 
system which is working to provide new tools 
for improved therapeutic outcomes, and 
safer prescribing patterns. Table 6 lists some 
relevant websites, for further reading.
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